U.S., Pfizer reach deal expanding American vaccine supply
By Isaac Stanley-Becker and Amy Goldstein
The Trump administration and Pfizer on Wednesday said they had reached an agreement supplying the United States with an additional 100 million doses of the coronavirus vaccine made by the pharmaceutical giant and the German company BioNTech by the end of July.
The deal doubles the total number of doses the government has on order from Pfizer — enough to immunize 100 million people with a two-dose regimen.
The additional doses are unlikely to mean an expansion of early access to the shots, which are being rationed for health-care workers and long-term care residents and staff as the coronavirus strains the country’s medical system. But the forthcoming larger supply — increasing by one-third the amount of vaccine available by mid-2021 — averts the possibility of a devastating shortfall in the spring and summer, right as the government was anticipating being able to make immunization available to wider segments of the public.